Inventor · disambiguated record
Michaela Fontenay
Also filed as: FONTENAY MICHAELA
6 granted patents·2 pending applications·4 citations·filing 2009–2020
71Inventor score
Files withINST NAT SANTE RECH MED3VIGUIE FRANCK2APOGENIX AG1APOGENIX GMBH1INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE1
Top patents by PatentIndex Score
8 records- 0178US9389233B2TET2 as a diagnostic and pronostic marker in hematopoietic neoplasmsVIGUIE FRANCK·Filed 2009·Granted Jul 12, 2016·3 cites·10 claims
- 0275US10662482B2TET2 as a diagnostic and prognostic marker in hematopoietic neoplasmsINST NAT SANTE RECH MED·Filed 2016·Granted May 26, 2020·1 cites·13 claims
- 0367US11203788B2TET2 as a diagnostic and pronostic marker in hematopoietic neoplasmsINST NAT SANTE RECH MED·Filed 2020·Granted Dec 21, 2021·0 cites·3 claims
- 0459US9540431B2Inhibitors of the CD95 signaling pathway for treatment of MDSAPOGENIX GMBH·Filed 2013·Granted Jan 10, 2017·0 cites·8 claims
- 0551US2017166648A1Inhibitors of the cd95 signaling pathway for treatment of mdsAPOGENIX AG·Filed 2016·Application pending·0 cites
- 0643US9675590B2Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromesINSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)·Filed 2015·Granted Jun 13, 2017·0 cites·2 claims
- 0743US9297046B2TET2 as a new diagnostic and pronostic marker in hematopoietic neoplasmsVIGUIE FRANCK·Filed 2012·Granted Mar 29, 2016·0 cites·7 claims
- 0838US2022119516A1Variants of erythroferrone and their useINST NAT SANTE RECH MED·Filed 2020·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →